|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. James Neil Phillips ChB, M.B.A., M.D., MB, MBA||CEO & Chairman of Management Board||427,6k||N/D||1962|
|Mr. Sebastian Werner||Member of Management Board & CFO||N/D||N/D||N/D|
|Ralf Penner||VP of Investor Relations & PR||N/D||N/D||N/D|
|Dr. Shaw Sorooshian||Sr. VP of Medical Affairs||N/D||N/D||1964|
|Dr. Thomas Stoehr||Sr. VP of Devel.||N/D||N/D||N/D|
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.
L'ISS Governance QualityScore di Paion AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.